C2I is home to over 25 biotechnology startups with the capability to provide more than 50 life science entrepreneurs a place to call home. Our residents have created over 100 highly skilled jobs and C2I had helped make an economic impact of 450M+ in funds raised in the Commonwealth.
AlpaLifeB Inc. focuses on both the U.S. and global markets to distribute nanobody reagents to research labs in academia and industry. They also provide customers with nanobody discovery services for the guarantee of generating high affinity and specific unique therapeutic nanobodies/VHH candidates from alpaca and llama against targets of interests.
Cellens is pioneering in label-free cell analysis with a combination of high-resolution nanoscale imaging and proprietary machine learning.
Anagenex is building a directed evolution platform to develop new small molecules by combining massively parallel biochemical experiments and machine learning.
Anastasis Bio is a research-stage company founded in 2020 to develop therapeutics inspired by the work of professors Denise Montell of UC Santa Barbara and Shoukat Dedhar of The University of British Columbia. Our research focuses on targeting novel pathways involved in tumor cell survival, proliferation, and metastasis.
A biotechnology company intended to develop human antibodies as therapeutics for infectious disease.
Revela is helping women struggling with hair thinning with their products using ProCelinyl™, the first and only ingredient that directly supports your hair follicles. Existing solutions support increased blood flow, DHT inhibition, and overall nutrition and wellness in hopes that your body will produce healthier hair. ProCelinyl focuses its attention directly on your follicles to effectively reawaken your roots.
Fosun Pharma, a leading healthcare group in China, strives to be one of the first-class enterprises in the global mainstream healthcare market.
Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. Alto, the world’s first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines.
DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. Their vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.
CreaGen Inc. is a premier chemistry-based drug discovery service company that provides cost-effective, high quality discovery research services to biotech and pharmaceutical companies.
Javelin Biotech creates predictive drug discovery platforms that merge human biology with computational biology to accelerate preclinical drug discovery and improve drug approval rates.
Building novel personalized medicines for autoimmune disease with targeted drug design.
Kebotix harnesses the power of its breakthrough platform that combines artificial intelligence and robotic automation to discover chemicals and materials significantly faster and more affordably.
Fluidic Analytics envisions a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being.
New Objective have been industry leaders in high-sensitivity LC-MS research through innovative life-science sample prep and delivery tools. Founded in 1997 on PicoTip® technology, New Objective has remained on the cutting edge of nanobore chromatography and nanospray-based mass spectrometry through engaging, ongoing communication with our customers, continuous innovation, and unwavering commitment to quality.